Chi­na’s top mR­NA con­tender is ready to go. And Soft­Bank just led a cash in­fu­sion push­ing it over the $1B line

With Mod­er­na and BioN­Tech of­fer­ing a mod­el — in the US and Eu­rope, re­spec­tive­ly — for how mR­NA biotechs can en­joy a me­te­oric rise to prof­it and fame with just one suc­cess­ful Covid-19 vac­cine, a Chi­nese play­er is ready to put it­self on the map.

Abo­gen, which set a record just three months ago with a $720 mil­lion Se­ries C, has now raised an­oth­er $300 mil­lion as it pre­pares to file its vac­cine can­di­date for au­tho­riza­tion. Part­nered with Wal­vax and Chi­na’s mil­i­tary, ABO-028M first en­tered clin­i­cal test­ing in the sum­mer of 2020 and is now in Phase III tri­als in Mex­i­co, In­done­sia and Nepal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER